CONMED Corporation (CNMD) News
Track canonical SquawkNews coverage tagged to CNMD, CONMED Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CNMD guides 6%-8% H2 2024 revenue growth on margin expansion
Management cites strong Q2 performance and confidence in 6%-8% revenue growth for H2 2024, citing AirSeal, BioBrace and international expansion. Margin expansion and robust free cash flow supported by sales and R&D inves
EARNINGS | Sep 09, 2026, 06:20 PM UTC
L
CNMD - CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
CNMD - CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 26, 2026, 08:13 PM UTC
L
CONMED to participate in Wells Fargo 21st Healthcare Conference
CONMED Corporation plans to participate in the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Aug 26, 2026, 08:05 PM UTC
L
CNMD Clearmind Medicine signs letter of intent to acquire 51% majority stake in EV Wireless Charging solutions for automated Parking systems
CNMD Clearmind Medicine signs letter of intent to acquire 51% majority stake in EV Wireless Charging solutions for automated Parking systems company Clearmind Medicine - deal valued at $2.50M for 51% majority stake - To
MNA | Aug 03, 2026, 12:02 PM UTC
L
CNMD Clearmind announces positive safety findings for cmnd 100, demonstrating consistent tolerability throughout full dose escalation in par
CNMD Clearmind announces positive safety findings for cmnd 100, demonstrating consistent tolerability throughout full dose escalation in part a of its FDA-regulated clinical trial Clearmind Medicine - all 24 participants
REGULATION | Jul 30, 2026, 12:32 PM UTC
L
Conmed Sees FY2026 Adj EPS $4.48-$4.60 vs $4.34 Est; Narrows FY2026 Sales Guidance from $1.350B-$1.375B to $1.358B-$1.373B vs $1.362B Est
Conmed (NYSE: CNMD ) is looking for FY2026 Adj EPS of $4.48-$4.60 vs $4.34 analyst estimate. Narrows FY2026 sales outlook from $1.350 billion-$1.375 billion to $1.358 billion-$1.373 billion vs $1.362 billion estimate.
EARNINGS | Jul 29, 2026, 08:20 PM UTC
L
CNMD - CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CNMD - CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
EARNINGS | Jul 29, 2026, 08:12 PM UTC
L
CNMD Conmed RESULTS: Q2, Q2 EPS $0.77, Q2 Income from operations $36.405M, Q2 pretax profit $31.347M, Q2 Net Income $23.071M, Q2 sales $343.
CNMD Conmed RESULTS: Q2, Q2 EPS $0.77, Q2 Income from operations $36.405M, Q2 pretax profit $31.347M, Q2 Net Income $23.071M, Q2 sales $343.488M vs. EST $337.6M, Q2 ADJ EPS $1.38 vs. EST $1.11
EARNINGS | Jul 29, 2026, 08:09 PM UTC